Teijin & Merz Deepen Japan Hold with Key XEOMIN® Neurological Approval

TOKYO & FRANKFURT – June 19, 2026 – In a move that underscores the power of long-term strategic alliances in the global pharmaceutical landscape, Japan's Teijin Pharma and Germany's Merz Therapeutics have secured a critical victory. Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved their drug XEOMIN® for two new therapeutic indications: cervical dystonia and blepharospasm. While any new treatment approval is noteworthy, this one is different. It represents the culmination of a near-decade-long partnership and a masterclass in navigating one of the world's most sophisticated and lucrative healthcare markets. This isn't just a win for patients; it's a calculated strike that reconfigures the competitive dynamics of Japan's neurology sector.

A New Lifeline for Thousands in Japan

Behind the corporate strategy and market share battles lies a story of profound human need. Cervical dystonia and blepharospasm are debilitating neurological movement disorders that severely impact quality of life. Cervical dystonia causes involuntary, often painful, contractions of neck muscles, leading to abnormal head postures and chronic pain. Blepharospasm involves uncontrollable spasms of the muscles around the eyes, which can become so severe as to render a person functionally blind.

In Japan, an estimated 28,000 people suffer from blepharospasm, with tens of thousands more affected by cervical dystonia. For these individuals, daily tasks become monumental challenges. Botulinum toxin injections have long been the first-line treatment, but the landscape has been limited. Research indicates that only about half of patients treated with existing botulinum toxins report high levels of satisfaction, with a significant minority discontinuing treatment due to unsatisfactory results or side effects. The approval of XEOMIN® introduces a vital new option, offering a different formulation that could provide a more durable or effective response for a new cohort of patients. As Masaki Taneda, President of Teijin Pharma Limited, stated, this approval allows the company to “offer an additional treatment option for patients whose daily lives can be significantly affected by these neurological conditions.”

The Anatomy of a Winning Alliance

This approval is the fruit of a partnership meticulously crafted in 2017. The exclusive license and co-development agreement between Teijin and Merz was a textbook example of synergistic strategy. Merz, a global specialist in neurotoxins, provided a world-class product and the weight of its global clinical trial data. Teijin, a Japanese industrial and healthcare conglomerate, brought its deep domestic market knowledge, established sales infrastructure, and critical expertise in navigating the MHLW’s stringent regulatory pathways.

This isn't their first success. The alliance has systematically expanded XEOMIN®'s footprint in Japan, indication by indication. The journey began with approval for upper limb spasticity in 2020, followed by lower limb spasticity in 2021, and chronic sialorrhea (excessive drooling) in 2025. These latest approvals for cervical dystonia and blepharospasm mark the fourth and fifth wins, demonstrating a methodical and relentless market penetration strategy. This step-by-step execution builds trust with regulators and clinicians alike, solidifying the product's position in the market. Stefan König, CEO of Merz Therapeutics, emphasized this point, noting, “This approval reinforces the value of our collaboration with Teijin Pharma and our shared focus on addressing unmet needs in neurological conditions worldwide, including Japan.”

Cracking the Code of Japan's $88B Pharma Market

Successfully launching and expanding a drug in Japan is no small feat. The country’s pharmaceutical market, valued at over $88 billion in 2026, is the third largest in the world, but it is notoriously difficult to penetrate. The botulinum toxin segment alone is a rapidly growing battlefield, projected to exceed $700 million by 2034, with some estimates putting its growth at an aggressive 11.3% CAGR. For years, this space has been dominated by giants like Allergan (an AbbVie company) and Ipsen.

The Teijin-Merz partnership’s success offers a blueprint for challenging this duopoly. By combining global science with local execution, they have effectively navigated the PMDA, Japan’s famously rigorous but efficient regulatory agency. Gaining five approvals in six years is a testament not only to the drug’s efficacy and safety but also to the partners’ regulatory acumen. It sends a clear signal to the market that a new, serious competitor is solidifying its territory. For investors, this demonstrates a de-risked and proven pathway to revenue in a high-barrier, high-reward environment. It confirms that with the right local partner, foreign innovation can thrive within Japan’s complex ecosystem.

The 'Pure Toxin' Advantage in Clinical Strategy

At the core of XEOMIN®'s clinical and commercial case is its science. The drug’s active ingredient, incobotulinumtoxinA, is produced using a proprietary process that removes complexing proteins, leaving only the purified neurotoxin. This is more than a manufacturing footnote; it's a key potential differentiator. For chronic conditions like dystonia that require repeated injections over many years, a patient's immune system can sometimes develop neutralizing antibodies to the botulinum toxin complex, rendering the treatment ineffective over time. The hypothesis is that a purified toxin, free of these extra proteins, may reduce the risk of this immunogenic response, preserving long-term efficacy.

The MHLW's approval was not granted on theory alone. It was underpinned by robust clinical data from Merz's global Phase III trials and, crucially, from specific Phase III trials conducted by Teijin within Japan. For blepharospasm, a dedicated study in Japanese patients confirmed sustained efficacy and safety over 48 weeks of repeated injections, meeting the primary endpoint and aligning with global results. This local validation is a non-negotiable for Japanese regulators and demonstrates a commitment to proving a product's worth for the nation's specific patient population. This scientific rigor, combined with a clear strategic vision, is precisely what it takes to bring better outcomes to patients and simultaneously drive market performance.